Taysha Gene Therapies's top three insider shareholders as of June 18, 2026 are R.A. Ii Session (President And Ceo, 8.87Mn shares), Sean P. Nolan (Chief Executive Officer, 2.91Mn shares), Paul B Manning (TenPercentOwner, 2.84Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Phillip B. Donenberg | - | 219,954 | 0 | 04 Jun, 2025 |
| Paul B Manning | - | 0 | 2,841,704 | 03 Jun, 2025 |
| Sean P. Nolan | Chief Executive Officer | 2,908,257 | 0 | 27 Jan, 2026 |
| Sukumar Nagendran | President And Head Of Rd | 1,317,389 | 0 | 27 Jan, 2026 |
| Suyash Prasad | Cmo And Head Of Rd | 530,589 | 0 | 07 Jul, 2022 |
| R.A. Ii Session | President And Ceo | 8,871,747 | 0 | 14 Jul, 2023 |
| John A Iii Stalfort | - | 1,155,224 | 0 | 04 Jun, 2025 |
| Laura Sepp-Lorenzino | - | 105,843 | 0 | 04 Jun, 2025 |
| Kamran Alam | Chief Financial Officer | 1,442,131 | 0 | 06 Feb, 2026 |
| Alison S Long | - | 105,843 | 0 | 04 Jun, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 10 Apr, 2026 | Sukumar Nagendran | Common Stock | A | 19,021 | $1.71 | 1,336,410 | D | M |
| 10 Apr, 2026 | Sukumar Nagendran | Common Stock | D | 200,000 | $4.46 | 1,136,410 | D | S |
| 10 Apr, 2026 | Sukumar Nagendran | Employee Stock Option (right to buy) | D | 19,021 | $0.00 | 455,920 | D | M |
| 04 Feb, 2026 | Kamran Alam | Common Stock | D | 1,655 | $4.52 | 1,442,131 | D | S |
| 23 Jan, 2026 | Sean P. Nolan | Common Stock | D | 136,789 | $4.75 | 2,949,569 | D | S |
| 23 Jan, 2026 | Kamran Alam | Common Stock | D | 78,968 | $4.75 | 1,467,635 | D | S |
| 23 Jan, 2026 | Sukumar Nagendran | Common Stock | D | 89,132 | $4.75 | 1,344,307 | D | S |
| 26 Jan, 2026 | Sukumar Nagendran | Common Stock | D | 26,918 | $4.61 | 1,317,389 | D | S |
| 26 Jan, 2026 | Kamran Alam | Common Stock | D | 23,849 | $4.61 | 1,443,786 | D | S |
| 26 Jan, 2026 | Sean P. Nolan | Common Stock | D | 41,312 | $4.61 | 2,908,257 | D | S |
| 12 Jan, 2026 | Sukumar Nagendran | Common Stock | A | 111,324 | $0.70 | 1,117,763 | D | M |
| 12 Jan, 2026 | Sean P. Nolan | Common Stock | A | 1,008,000 | $0.00 | 3,086,358 | D | A |
| 12 Jan, 2026 | Kamran Alam | Common Stock | A | 359,000 | $0.00 | 1,546,603 | D | A |
| 12 Jan, 2026 | Sukumar Nagendran | Common Stock | A | 88,676 | $1.71 | 1,206,439 | D | M |
| 12 Jan, 2026 | Kamran Alam | Employee Stock Option (right to buy) | A | 231,000 | $0.00 | 231,000 | D | A |
| 12 Jan, 2026 | Sean P. Nolan | Employee Stock Option (right to buy) | A | 648,000 | $0.00 | 648,000 | D | A |
| 12 Jan, 2026 | Sukumar Nagendran | Common Stock | D | 200,000 | $4.71 | 1,006,439 | D | S |
| 12 Jan, 2026 | Sukumar Nagendran | Common Stock | A | 427,000 | $0.00 | 1,433,439 | D | A |
| 12 Jan, 2026 | Sukumar Nagendran | Employee Stock Option (right to buy) | D | 111,324 | $0.00 | 111,359 | D | M |
| 12 Jan, 2026 | Sukumar Nagendran | Employee Stock Option (right to buy) | D | 88,676 | $0.00 | 474,941 | D | M |